Sanofi
4Q Revenues: $11.0 billion (+9%)
4Q Earnings: $2.7 billion (+13%)
FY Revenues: $43.2 billion (+3%)
FY Earnings: $11.4 billion (+5%)
Comments: In the quarter pharmaceutical sales were $9.3 billion (+11%), which includes the contribution of $1.1 billion from Genzyme, as well as the impact of generic competition to Lovenox (-13%), Ambien CR (-14%), Taxotere (-68%). For the year pharmaceuticals sales were $36.1 billion, up 7%. Vaccines sales were up 7% (excluding A/H1N1 sales) to $4.5 billion for the year. Diabetes revenue grew 12% in 2011 to $1.6 billion. Genzyme sales (consolidated from April 1, 2011) increased 8% to $3.1 billion for the year. Consumer Health Care and Generics revenue grew 23% to $3.5 billion, and 16% to $2.3 billion, respectively.
4Q Revenues: $11.0 billion (+9%)
4Q Earnings: $2.7 billion (+13%)
FY Revenues: $43.2 billion (+3%)
FY Earnings: $11.4 billion (+5%)
Comments: In the quarter pharmaceutical sales were $9.3 billion (+11%), which includes the contribution of $1.1 billion from Genzyme, as well as the impact of generic competition to Lovenox (-13%), Ambien CR (-14%), Taxotere (-68%). For the year pharmaceuticals sales were $36.1 billion, up 7%. Vaccines sales were up 7% (excluding A/H1N1 sales) to $4.5 billion for the year. Diabetes revenue grew 12% in 2011 to $1.6 billion. Genzyme sales (consolidated from April 1, 2011) increased 8% to $3.1 billion for the year. Consumer Health Care and Generics revenue grew 23% to $3.5 billion, and 16% to $2.3 billion, respectively.
